Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

In a gripping new release from Skyhorse Publishing, molecular biologist and whistleblower Becky McClain lays bare her harrowing journey in "Exposed," a book that promises to shake the foundations of ...

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend ...

Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the ...

President Donald Trump’s new partnership with Pfizer to sell drugs directly to consumers is being cast as a major ...

Mixed options sentiment in Pfizer (PFE), with shares down 22c near $24.55. Options volume relatively light with 22k contracts traded and calls ...

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

U.S. Investment Forum 2025, a renowned era that has significantly unfolded the relationship between the Kingdom of Saudi ...

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by ...

He stipulated that the honoree should be a force for good, and selected Pfizer Chairman Albert Bourla for his innovation, ...

Pfizer faces lawsuits from 1,000 women alleging Depo-Provera birth control caused brain tumours, amid new research showing ...